There are three general options for management of acute myeloid leukemia (AML): standard therapy, investigational therapy or no treatment other than supportive care. Given AML's natural history and the uncertain results inherent in investigational therapy, most patients intuitively prefer standard therapy, by which is usually meant 3 þ 7 or low-dose cytarabine. However, this preference assumes results with standard therapy are 'satisfactory'. Results with standard therapy of AML are, however, so variable that it is difficult to speak of a single result. Therefore, I review prognostic factors with standard therapy to permit physicians to better inform patients of the likely outcome with such therapy, realizing that the same data might prompt one patient/physician to prefer standard therapy and another investigational therapy under the assumption that although plausibly worse than standard the latter cannot be that much worse. Because even in patients aged 475 years, the principal cause of therapeutic failure is resistance to therapy not treatment-related mortality, I emphasize factors associated with resistance, principally a 'monosomal karyotype' and various molecular markers and extend the European Leukemia Net prognostic system. I also stress the value of waiting for cytogenetic and molecular results before beginning induction therapy and review various investigational options.
INTRODUCTION
All patients with acute myeloid leukemia (AML) require supportive therapy, principally transfusions and antibiotics. This aside there are, broadly speaking, three options for management of AML: standard therapy, investigational therapy or no therapy other than supportive care. Survival expectations with the latter are difficult to gauge as it is usually reserved for those patients judged unable to tolerate specific anti-AML therapy. Clinical observation suggests, however, some newly diagnosed patients may live 12 --18 months with supportive care only, particularly if they present with low white blood cell (WBC) counts and thus relatively low risk of leukostasis or of infiltration of organs such as lung or brain. This is certainly longer than the 4 --6 months noted when Freireich et al. 1 described the natural history of AML in 1961 with the improvement in a result of superior supportive care. Nonetheless and particularly in light of the general population's lengthening life expectancy, there is no doubt that AML has an overwhelming impact on life expectancy. Furthermore, the untreated disease often produces severe morbidity due to infections and the need for frequent transfusions, not to mention the absence of hope associated with attempts to treat the underlying disease.
Hence, the first thought in any patient with AML should revolve around the choice of anti-AML therapy. Naturally enough patients prefer standard therapy to investigational therapy. This preference reflects the possibility that investigational therapy will be worse than standard; absent this possibility randomized trials comparing standard and investigational treatments would be ethically problematic. Furthermore, for reasons detailed in reference, 2 reports of 'promising' new therapies often do not stand the test of time. Because of the resultant uncertainty regarding the results with any given investigational therapy, the decision to opt for investigational therapy must rest on dissatisfaction with the (well-known) results of standard therapy. Simply put, the patient must be judged as at such high risk after standard therapy that the physician and patient are convinced to risk the use of investigational therapy, feeling that it cannot be that much worse than standard. Hence, upon seeing a patient with AML I view my principal task as conveying the likely outcome with standard therapy, while realizing that the same data might lead one patient to choose standard, and another investigational, therapy. Standard therapy usually means cytarabine (ara-C) given continuously for 7 days at 100 mg/m 2 daily together with 3 days of an anthracycline; I will refer to this hereafter as '3 þ 7'. The anthracycline is typically daunorubicin or idarubicin, with most studies suggesting little difference between these drugs when given at equivalently toxic doses.
TREATMENT-RELATED MORTALITY VS RESISTANCE IN DEFINING HIGH-RISK AML FOLLOWING STANDARD THERAPY
The outcome of most interest to patients is survival. Death in AML is due to either treatment-related mortality (TRM) or resistance to treatment. TRM has been variably defined as occurring within the first 1 --2 months after initiation of treatment. Data indicate that with 3 þ 7 the risk of death is highest in the first 4 weeks after treatment begins after which if declines sharply. 3, 4 This suggests that death occurring within 4 weeks is a reasonable operational criterion for TRM. Conversely, patients who live at least 28 days but fail to enter complete remission (CR) or who relapse after achieving CR can be considered resistant. Furthermore, the marked decline in TRM after 4 weeks suggests that patients who die during this time are qualitatively distinct. Further support for this hypothesis derives from dissimilarity between the factors ('covariates') associated with TRM and those associated with resistance.
The principal factor associated with TRM is performance status. Others adding to ability to forecast are age, bilirubin, creatinine and platelet count. 4 Areas under receiver operating characteristic curves provide a method to quantify predictive ability. An area under the curve (AUC) of 1.0 denotes perfect prediction while an AUC of 0.5 is equivalent to a coin toss. Inclusion of all the covariates listed above results in an AUC of 0.82 for predicting TRM. In contrast, performance status alone has an AUC of 0.65 and age alone an AUC of 0.62, suggesting that systems that use only a single covariate to predict outcome are suboptimal. Although age is commonly used to determine which treatment protocol a patient is eligible for, removal of age from the 'complete' model described above results in reduction of the AUC from 0.82 to only 0.81. The role of co-morbidities in predicting TRM remains incompletely explored. Sorror 6, 7 has reported the profound role played by such co-morbidities in determining TRM after allogeneic hematopoietic cell transplantation (HCT).
The chief cause of treatment failure in AML is resistance to therapy, not TRM. This is also true in older patients despite common perception and the resultant current emphasis on reducing toxicity in these patients. For example, Appelbaum et al. 8 reported that, following administration of standard 3 þ 7 induction therapy, resistance defined as failure to enter CR despite living at least 30 days was responsible for 71% of induction failures in patients younger than age 56 years, 61% in patients age 66 --75 years and 54% in patients age 475 years. When the 5-to 6-fold higher rates of relapse than of death in remission are accounted for, 9 the importance of resistance is even more apparent. A trial randomizing patients aged over 65 years to a 3 þ 7-like regimen or 'low-dose ara-C (LDAC)' found that LDAC reduced both early death and CR rates resulting in similar survival. 10 This suggests that reduction in toxicity may be of little value if not accompanied by an increase in efficacy. Given the primacy of resistance we will largely define high-risk AML based on presence of factors associated with high risk of resistance to standard therapy.
FACTORS ASSOCIATED WITH RESISTANCE TO STANDARD THERAPY Cytogenetics Leukemia cell karyotype remains the principal predictor of outcome in AML. For many years, patients with À5, À7, del 5q, del 7q, t(3;3), inv(3), t(6;9), an abnormality involving 11q or 17p, or a complex karyotype (at least three separate clonal abnormalities) were classified as comprising the worst group. More recently, a monosomal karyotype (MK), criteria for which are at least two autosomal monosomies, or a single autosomal monosomy together with structural changes (as opposed to gains or losses of whole chromosomes) has been found associated with the worst outcomes 11, 12 ( Figure 1 ). For example, 4-year survival probabilities with a complex karyotype were 13% without and 0% with MK (Po0.01). 12 The Southwest Oncology Group found that CR rates with 3 þ 7 for patients age 31 --40, 41 --50, 51 --60 and 460 years of 60, 67, 52 and 27% in the absence of MK vs 27, 14, 24 and 14% with an MK. 12 
Molecular markers
Intermediate prognosis cytogenetics are those other than described above and other than inv(16), t(8;21), t(16:16), which are considered 'favorable'. The most common abnormality in the intermediate group is þ 8, while the most common finding is normal karyotype (NK). The latter patients have traditionally had the most variable prognoses with standard therapy. However, it is now clear that patients with de-novo NK newly diagnosed AML de novo can be divided into those with 'high' and 'low' risks of relapse-free survival (RFS) and survival according to the presence/ absence in AML blasts of internal tandem duplications (ITDs) in the Fms-like tyrosine kinase 3 gene (FLT3 ITD), mutations in exon 12 of the nucleophosmin 1 (NPM1) gene, and mutations---particularly double mutations---in the CCAAT enhancer-binding protein (CEBPA) gene. 13 In particular, those of such patients with (a) an NPM1 mutation, but no FLT3 ITD or (b) a CEBPA mutation is in a 'low-risk' group, whereas other patients are in a 'high-risk' group ( Figure 2) .
Most of the data about the prognostic effect of FLT3, NPM1 and CEBPA has been obtained in patients aged o60 years with NK de-novo AML. However, the Cancer and Acute Leukemia Group B has observed a negative prognostic effect of FLT3 ITD in patients aged 60--69 years (although this appears to be less in patients aged 70 years or above) 14 and a favorable effect of NPM mutations in patients aged 60--69 years and particularly aged 70 years or above. 15 Table 1 uses the cytogenetic and molecular information described so far in this chapter to place patients in five groups according to risk of resistance to standard therapy, with resistance defined as failure to enter CR despite surviving X28 days from start of therapy or relapse from CR. The system differs slightly from that suggested by the European Leukemia Net 16 in that it recognizes the unique significance of MK, weighs FLT3 ITDs somewhat more unfavorably than the ELN, uses CKIT mutation status 17, 18 and various clinical parameters 19 --21 to discriminate among patients with 'favorable' cytogenetics. For practical purposes, patients in the intermediate 2, intermediate 3 and worst categories can readily be considered to fall into a high-risk group since despite occasionally having CR rates 450% (intermediate 2 and 3 groups), their chance of remaining in remission for 2 --3 years, beyond which patients may be operationally considered 'potentially cured' 22 is o5% (worst group) to 30% (intermediate 2 and 3 groups). As noted above what constitutes 'high risk' to one patient may not do so to another. Similarly, some patients in the intermediate 1 group may consider themselves at high risk; for example, a patient who has inv(16) but also a CKIT mutation or a patient with NK AML who does not have an NPM1 mutation, and thus, despite the absence of an FLT3 ITD, may only have a potential cure rate of 35 --50%.
SYNTHESIS OF PRE-TREATMENT CYTOGENETICS AND MOLECULAR MARKERS TO DEFINE HIGH-RISK AML WITH STANDARD THERAPY

USE OF POST-TREATMENT DATA TO ASSESS RISK
Analyses using AUC analogous to those described above for TRM indicate that even accounting for presence/absence of FLT3 ITD, cytogenetics and clinical parameters such as age and secondary AML WBC count our ability to identify resistant patients is closer to a coin flip than certainty (AUC 0.72). 4 As with TRM, removal of age from models predicting resistance has little effect on AUC. The difficulty forecasting resistance is prima facie evidence for the need of randomization in AML trials.
The ability to predict resistance will likely be improved by analyses of mutation status of genes such as DNMT3a, IDH1/2 or TET and of expression of genes such as BAALC, ERG and MN1. 22 However, I believe most improvement will come from assessment of initial response and its incorporation with pre-treatment data. An obvious example is duration of first remission (with primary refractory patients assigned a CR duration of 0), which is the principal predictor of response to second-line ('salvage') therapy. 23, 24 In patients in CR assessment of the level of minimal residual disease (MRD) will likely prove critical. Numerous studies indicate that multiparameter flow cytometry, 25 or PCR for molecules such as WT1 26 or NPM1 27 provide a sensitive and specific means to detect impending relapse in patients in CR by morphologic criteria. Figure 3 illustrates the value of incorporating MRD status after completion of consolidation therapy with pretreatment cytogenetic information; 28 the same is true in patients who are FLT3 ITD negative at diagnosis. 28 Hence, patients in CR but with such MRD, particularly if persistent, or present at a relatively high level, should be considered a high-risk group and ipso facto candidates for hematopoietic cell transplant (HCT) or investigational therapies.
MY APPROACH TO HIGH-RISK AML
AML is not always an emergency Given their role in predicting response to standard therapy and hence in advising patients as to whether they might be better served by receiving investigational therapy, NPM1, FLT3 and, where practical, CEBPA status should be determined before beginning therapy in much the same way as cytogenetic status. Except in patients requiring emergency treatment (for example, those with WBC 450 000, a rapidly rising WBC or evidence of leukostasis, lung or brain infiltration) strong consideration should be given to using cytogenetic and molecular information not only in planning post-remission therapy but in planning induction therapy in patients in the intermediate 2, intermediate 3 and worst groups of Table 1 . Several considerations are relevant here. First, it seems useful to avoid giving 3 þ 7 to patients in whom the CR rate is likely to be o50% such those even aged o55 years with a complex karyotype and/or À5, À7, del 5q or del 7q, 29 and in particular an MK. 12 This is even more the case in older patients in whom not only may the CR rate be oo50% with such therapy but who may incur TRM before a second therapy can be given. Second, data from studies assessing the role of higher doses of daunorubicin 30, 31 or ara-C 32,33 do not suggest that dose increases will materially abrogate the effect of unfavorable cytogenetics or an FLT3 ITD. Third, even if patients obtain CR with 3 þ 7, induction regimen can influence duration of CR as well as its achievement, and this is true even if HCT is done in CR. 34 Strikingly, the presence of MRD as measured by multiparameter flow cytometry before HCT in CR1 increases relapse rate after HCT, independently of cytogenetics. 35 The presence of such MRD reflects the ineffectiveness of therapy given before HCT. Therefore, relapse rates, including those after HCT, might be reduced if even younger highrisk ( trials; an example would be use of newer FLT3 inhibitors such as AC220 together with standard 3 þ 7.
An obvious risk in waiting for cytogenetic and molecular information to become available before initiation of treatment is clinical deterioration during this time. Examining the effect on outcome of time from diagnosis to therapy in 1361 patients with newly diagnosed AML and WBC count o50 000 Sekeres et al. found that after accounting for other covariates associated with outcome, time from diagnosis to therapy (median only 4 days) had no influence on CR or survival in patients age X60 years and a deleterious effect on survival after 6 months in younger patients, which was much less than that associated with cytogenetics. 36 The risk associated with delaying therapy in younger patients should be weighed against that associated with giving suboptimal induction therapy to patients with unfavorable cytogenetics because of a perceived need to treat the patient promptly.
Which investigational induction therapy?
The decision to use an investigational therapy after concluding that results with standard therapy, including higher doses of daunorubicin 30, 31 or ara-C, 32, 33 are unlikely to be satisfactory is much easier than the decision as to choice of investigational regimen. The very fact that so many trials for high-risk AML are ongoing suggests that no one is sure which is best. Also contributing to the difficulty is the observation that initially promising results typically do not ultimately translate into meaningful improvements in survival and are often even difficult to reproduce. 2 Under these circumstances, I tend to use the patient's probability of TRM to help decide which new investigational therapy might be preferred, as indicated in Table 2 . It is important to recall that age is just one of several factors contributing to TRM (and resistance) and that it may to some extent be a surrogate for other factors. 4 In particular, several prognostic systems suggest that patients aged 60 years or greater cannot infrequently tolerate 'intensive therapy' and may even benefit from 3 þ 7 if, for example, in the best or intermediate 1 prognostic groups of Table 1 .
5,37 --40
What about clofarabine and 'hypomethylating agents'? The Polish Acute Leukemia Group has reported a randomized study showing that addition of cladribine to 3 þ 7 (daunorubicin 60 mg/m 2 daily Â 3) produced a higher rate of CR after a single course despite similar or less toxicity. 41 However, a trial (CLASSIC 1) randomizing similar patients age 55 years or above to high-dose ara-C ± clofarabine found that while CR rates were higher with the combination survival was not, as a result of more TRM in patients given the combination. It might be possible to identify patients who are at relatively high risk of TRM 4 and exclude them from treatment with the combination. Burnett et al. 42 have found that, after adjusting for other covariates, CR and survival rates in 106 newly diagnosed patients (median age 71 years) considered unfit for 3 þ 7 and thus given clofarabine were higher than when similarly unfit patients received LDAC; however, the differences in survival were perhaps more noteworthy statistically (P ¼ 0.003) than medically (median improvement 1 --2 months). Clofarabine in unfit patients gave essentially identical survival as 3 þ 7-like therapy in fitter older patients with unfavorable cytogenetics, but of course this itself is suboptimal (median 6 months). In 70 relatively fit patients (median age 71 years) randomized to clofarabine or clofarabine þ LDAC, the combination produced superior CR (63 vs 31%) and survival rates, but survival remained short (median 11 months), even with the combination. 43 Further information about clofarbine's role in newly diagnosed AML will likely be forthcoming from an ongoing Eastern Cooperative Oncology Group study randomizing older patients to 3 þ 7 or clofarabine, albeit without ara-C. This omission is, in my opinion, unfortunate as the drug's future in induction therapy almost certainly lies in combination with ara-C and perhaps other drugs. Accordingly I would only use clofarabine in such circumstances.
Azacitidine and decitabine were first investigated in patients with MDS some of whom had 21 --30% blasts and were thus reclassified as newly diagnosed AML. In the azacitidine trial, physicians first declared a preference for supportive care only, LDAC, or 3 þ 7 in a given patient. Patients were then randomized to the selected conventional care regimen or azacitidine. Among 113 AML patients (median age 70 years), median survivals were 24.5 months (azacitidine) and 16.0 months (conventional care) and were 12 months (azacitidine) and 5 months (conventional care) in the patients with unfavorable cytogenetics. 44 Too few patients received LDAC or 3 þ 7 to permit robust comparisons with azacitidine. However, unlike what has been observed with 3 þ 7, 45 achievement of CR did not seem a precondition for longer survival.
Results of a trial randomizing patients aged X65 years between decitabine at the commonly used dose of 20 mg/m 2 daily days 1 through 5 and physician's choice of LDAC or supportive care only were presented at the 2011 meeting of the American Society of Clinical Oncology. 46 An 'updated unplanned analysis' performed after 92% of patients had died showed median survival of 7.7 months for decitabine and 5.0 months for physicians' choice ('nominal P ¼ 0.03') The previously planned 'final analysis' done after 82% of patients had died showed the same median survivals but P ¼ 0.10.
Based on these data, it is plausible that regulatory agencies will approve azacitidine or decitabine for use in newly diagnosed patients aged X60 years with newly diagnosed AML. While I would have no problem with such approval, I think it would be unfortunate if these drugs were regarded as the 'standard of care' for such patients if this phrase meant not a standard of comparison for future trials, but a mandate to use these drugs as initial therapy, rather than placing a patient on a clinical trial, such as one using these drugs as 'epigenetic priming'. 47 Because the results noted above likely reflect an average of results from more and less sensitive patients it is important to identify patients who are more likely to respond. Administering decitabine at 20 mg/m 2 for 10 days, Blum et al. 48 noted a CR rate of 67% in 27 patients with unfavorable cytogenetics, a much higher rate than with the usual 5-day schedule. Although median survival was not reported for these patients, it was 1 year for all 53 patients (median age 74 years). Responders had higher expression of miR-29b, presumably reflecting miR-29b's ability to downregulate enzymes involved in methylation. It remains unclear, however, whether response to hypomethylating agents correlates with hypomethylation and, in particular, with re-expression of silenced genes. Such a correlation might encourage further studies combining hypomethylating agents and histone deacetylase inhibitors, which appear to cooperate with hypomethylating agents in inducing re-expression of silenced genes.
Post-remission therapy Hematopoietic cell transplantation. A fundamental question is whether to proceed to HCT in patients in first CR (CR1). Because autologous HCT and chemotherapy in CR1 is generally held to afford similar survival, 49 my thoughts turn to allogeneic HCT; hereafter I will mean allogeneic HCT when I refer to HCT.
HCT in CR1 is done most frequently in patients age o60 who typically in first CR receive a 'myeloablative HCT'. Depending largely on co-morbidities as described by Sorror. 6,7 mortality rates in the first 100 days after HCT may be as low as 10%, which nonetheless is considerably higher than seen in patients receiving post-remission chemotherapy. 9 However, if the increase in TRM with HCT is more than offset by a decrease in relapse risk (although relapse is the principal cause of failure after HCT as well as chemotherapy), survival should be better with HCT. To avoid bias favoring HCT, comparisons of chemotherapy and HCT typically compare patients with and without donors; if the donor group does better so would patients actually given HCT, with the results in such patients setting an upper limit on the effectiveness of HCT. However, donor-no donor comparisons are problematic. 50 A preferable technique for avoiding bias would be to consider all patients in the no donor group with those found to have a donor right censored from the no donor group and left censored into the donor group on the date that a match is identified. 51 However, this is logistically difficult compared with the donor --no donor method. Using the latter, Koreth et al. did a meta-analysis to assess RFS and survival in patients receiving an HLA-matched myeloablative transplant in CR1 rather than chemotherapy or an autologous transplant. 52 The median age of the patients was B40 (all were o60 years) and their median follow-up was 4 --5 years. In only one trial considered in the meta-analysis, did o60% of patients with donors receive HCT. The results showed that both RFS and survival (Table 3) were superior in the donor group if patients had intermediate or worse cytogenetics while there was no benefit in patients with inv(16) or t(8;21). Again, the results are perhaps less significant medically than statistically. For example, assume a patient with unfavorable cytogenetics would survive 1 year after achieving CR if given chemotherapy or an autologous transplant. A reduction in hazard rate to 0.73 (Table 3) translates into a survival of 16.4 months. Hence, while the objective should be to perform myeloablative HCT in as many patients aged o60 years as possible, means to reduce relapse after HCT are needed; some of these are noted below. An alternative approach to immediate HCT would be to reserve HCT for patients with increasing evidence of MRD; 53 presumably, the criteria for 'MRD' would have to be liberal given that immediate HCT is the 'default' treatment. An advantage of the delayed strategy might be avoidance of late complications of HCT. In particular, in patients cured of their AML HCT is associated with a 30% decrease in life expectancy. 54 Of course, this is preferable to relapse and consequent more immediate death. Hazard rate o1.0 favors allogeneic HCT.
How to manage high-risk acute myeloid leukemia EH Estey Less is known about the role of HCT in high-risk patients as defined by molecular abnormalities. Schlenk et al. 13 noted longer RFS, but not survival, in NK patients younger than age 60 years who had a sibling donor and were neither CEBPA mutated nor NPM1 mutated/FLT3 wild type. In contrast, donor --no donor analyses suggested no benefit for HCT in patients who had a CEBPA mutation or who had an NPM1 mutation but no FLT3 ITD 13 ( Figure 4 ). Although finding a negative effect of FLT3 ITD in both patients who were and were not transplanted, Gale et al. 55 reported a reduced cumulative incidence of relapse, but not improved survival, in the former.
Many patients do not have matched-HLA sibling donors. However, modern typing techniques have allowed matched unrelated donors to be identified for most patients without sibling donors. 56 Although a true comparison of matched sibling and matched unrelated donor HCT would require randomization of patients with sibling donors to receive transplant from the sibling or a matched unrelated donor such a trial is not feasible. With this constraint and bearing in mind, the increased difficulties with donor --no donor analyses in the unrelated setting, data suggest equivalent results with matched sibling and matched unrelated HCT 57, 58 and that if HCT from a (living) matched unrelated donor is not feasible, double cord blood transplants are (at least) their equivalent. 59 The past 20 years have also seen the development of reduced intensity conditioning (RIC) regimens. 60 These reduce toxicity but permit engraftment and subsequent development of T-cell mediated graft-vs-AML effects and allow patients in their 1970s or with significant co-morbidities to receive HCT. Analyzing 274 patients (median age 60 years, up to age 74 years) who received RIC-HCT from 1998 to 2008, Gyurkocza et al. 61 noted non-relapse mortality rates of 4, 16 and 26% at 100 days, 1 year and 5 years, with non-relapse mortality chiefly from graft-vs-host disease. Relapse accounted for 60% of the deaths and with a median follow-up of 38 months the probability of 5-year survival was 37% for patients transplanted in CR1, 34% for those transplanted in CR2 and 18% for patients with more advanced and refractory disease. Five-year survival rates were similar in patients with matched sibling (37%) and matched unrelated donors (33%).
These results certainly suggest that RIC-HCT is superior to chemotherapy in older patients in CR1 or CR2, and indeed a donor --no donor analysis in CR1 has suggested the same. 62 However, related to the inability of such an analysis to completely account for bias is the question of the general applicability of RIC-HCT 63 or of even myeloablative HCT. A forthcoming US Intergroup study will address the latter question. It is also noteworthy that at least some of the covariates that predict relapse after chemotherapy, such as worst cytogenetics and CRp rather than CR do the same after HCT, 61 suggesting that these modalities are not as different as might be hoped. Nonetheless, it is clear that the mortality after HCT is decreasing (41% from 1993 to 1997 vs 2003 --2007) 64 after adjustment for covariates such as age and co-morbidities.
These data lead me to recommend HCT in CR1 for patients in the intermediate 2, intermediate 3 or worst prognostic groups in Table 1 . The upper age limit might be 75 --80 years, assuming no co-morbidities. If a matched sibling donor is unavailable, then I recommend use of matched unrelated donors or cord blood HCT and, in patients in the intermediate 3 and worst groups use of haploidentical donors. 65 Nonetheless, in almost all these cases HCT should be combined with therapies to decrease post-HCT relapse. These include more effective/less toxic conditioning regimens or immunologic augmentation of the post-HCT graftvs-AML effect. Examples of the former include use of radiolabeled antibodies to CD45. 66 Immunologic augmentation might be achieved using T cells specific for well-defined AML associated antigens such as WT1, or for minor histocompatibility antigens expressed on host hematopoietic cells but not cells affected by graft-vs-host disease. 67 Other approaches. Likewise, immunologic approaches might be used as post-remission therapy outside the RIC-HCT setting. For example, Brune et al. 68 randomized 320 patients (80% in first, 20% in subsequent, CR) to receive either an IL-2 --histamine combination or no further treatment after completion of maintenance therapy and typically 4 --5 months after entering CR. IL-2 þ histamine prolonged survival and RFS by a median of 4 --6 months in CR1 patients. Although as often the case the improvement in RFS but not survival was significant at Po0.05, the data prompted the European Medicines Agency to approve IL-2 þ histamine for patients in CR1.
Most new therapies are first tested either in relapsed AML, AML that has not entered CR with initial therapy, or patients aged X60 years with newly diagnosed AML many of whom have unfavorable cytogenetics and/or secondary AML. This practice may make it harder to discover effective new therapies. To increase the chance of discovering effective new drugs, I would advocate investigation of new drugs in patients in CR with or without MRD. There is some movement in this direction. Examples are ongoing studies of decitabine or bortezomib. Furthermore, the future is likely to see increasing use of agents whose mode of action, such as specifically targeting AML 'stem cells', suggest they would be most effective in patients with relatively small amounts of disease, for example, those in CR. 69 Instead of being viewed separately, 'HCT' and 'non-HCT' approaches will be combined to prolong CR. Examples are the prophylactic use of azacitidine, 70 or of the FLT3 inhibitor AC220, 71 in patients at high risk of relapse after HCT.
Management of relapsed/refractory AML Here, again the fundamental decision is between a standard (re-induction) regimen such as FLAG or mitoxantrone þ etoposide, or an investigational regimen. The principal predictor of response to standard therapy is duration of first CR, with 'primary refractory' patients assigned CR duration of 0. Estey et al. 23 reported that patients about to receive their first re-induction attempt (first salvage) had a CR rates of 60% (15 patients), 40% (30 patients) and 15% (160 patients) if their first CR durations were 42 years, 1 --2 years, and o1 year, respectively. Patients who were about to receive more than first salvage with a first CR o1 year had essentially no chance of attaining a CR (58 patients, 96 salvage attempts 0 CR). Focusing more on survival, Breems et al. 24 developed a prognostic score based on 667 patients in first relapse. The score accounted for CR duration (418 months 0 point, 7 --18 months 3 points and o7 months 5 points), cytogenetics (inv(16) 0 point, t(8;21) 3 points, other 5 points), age (o36 0 point, 36 --45 1 point and 445 2 points) and prior allogeneic or autologous transplant (no 0 point and yes 2 points). As seen in Figure 5 , most patients were in the worst group and clearly are candidates for investigational salvage regimens. Figure 5 . Survival from first relapse according to prognostic score: group A 1 --6 points, group B 7 --9 points and group C 10 --14 points. See text and reference. 24 How to manage high-risk acute myeloid leukemia EH Estey
